S. Fedele

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals

A. Owen, M. Boffito, M. Mcclure, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

C. Brander, V. Miller, T. Peto, 2021, Cell reports.

Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care

Sajjida Jaffer, G. Donaldson, M. Nelson, 2022, The Lancet Respiratory Medicine.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, 2019, The Lancet.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

Age, time living with diagnosed HIV infection, and self‐rated health

A. Nardone, L. Haddow, R. Gilson, 2016, HIV medicine.

Accuracy of self‐report of HIV viral load among people with HIV on antiretroviral treatment

A. Nardone, L. Haddow, A. Phillips, 2016, HIV medicine.

Pharmacokinetics of once-daily doravirine over 72 h following drug cessation.

A. Milinkovic, M. Boffito, M. Mcclure, 2020, The Journal of antimicrobial chemotherapy.

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.